Feeds:
Posts
Comments

Preliminary Agenda Available: World Preclinical Congress 2017 (June 12-16 in Boston, MA)

Reporter: Aviva Lev-Ari, PhD, RN

 

 

The preliminary agenda is now available for CHI’s 16th Annual World Preclinical Congress taking place June 12 – 16, 2017 at The Westin Copley Place in Boston, MA.

In recent years, the World Preclinical Congress (WPC) has turned into a key networking event for those involved in preclinical research. It features conferences, training seminars and short courses that cover the very latest in preclinical strategies and technologies, to enable better and faster decisions in drug discovery. WPC attracts a diverse, global audience, which include experts, as well as people who are new and eager to contribute to the field.

Now in its 16th year the event will continue to highlight ways to improve accuracy and efficiency in preclinical research, while bringing together the people and technologies to make it happen. Spanning five days, the event attracts 1,000+ attendees including chemists, biologists, pharmacologists, toxicologists, screening and formulation experts.

This year’s event is comprised of 14 conference tracks, 5 Symposia, 10 short courses*, interactive breakout discussion groups, an exhibit hall featuring more than 80 technology and service companies, Student Fellowship Program and dedicated poster viewing and networking sessions. The 16th Annual World Preclinical Congress event assembles an impressive group of distinguished speakers who look forward to sharing their knowledge, best practices, and expertise with all attendees.

Don’t miss your opportunity to network with 1,000+ of your peers at this year’s event. Special early registration savings are currently available.

We look forward to seeing you this June in Boston, Massachusetts.

Sincerely,

Bethany Gray

Director of Product Marketing

Cambridge Healthtech Institute

SOURCE

From: Bethany Gray <bethanyg@worldpreclinicalcongress.com>

Date: Monday, December 5, 2016 at 2:15 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Preliminary Agenda Available: World Preclinical Congress 2017 (June 12-16 in Boston, MA)


We’re seeing an acceleration of M&A activity and a growing IPO pipeline through the end of 2016, but the bar remains high.

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Here’s what one top VC firm predicts will happen to tech startups in 2017

Accel is an early & growth-stage venture capital firm and is known for its investments in Facebook, Slack, and Dropbox. This is the firm’s annual presentation on what the tech environment is like for founders today and what will happen in 2017, republished with permission.

  1. It’s an incredible time to be a technology entrepreneur.
  2. A rising “new guard” are officially the most valuable companies in the world: Apple, Alphabet/Google, Microsoft, Amazon, Facebook.
  3. But of course, it’s important to stay disciplined.
  4. We’re seeing an acceleration of M&A activity and a growing IPO pipeline through the end of 2016, but the bar remains high.

 

*In order as of 11/22/16:

  • Apple — $596B
  • Alphabet/Google — $551B
  • Microsoft — $478B
  • Amazon — $372B
  • Facebook — $348B

**Bloomberg dug into the numbers here too.

 

SOURCE

http://www.businessinsider.com/accel-2017-vc-predictions-2016-11


Top Authors for All Days ending 2016-12-01: GROWTH Trends @Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

Curator: Aviva Lev-Ari, PhD, RN

 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016 1,107,643  4,972 3,398  2,279

Be proud to be part of this team !!!

Forthcoming SEVEN e-Books in 2016 AND Eight e-Books on Amazon.com

https://pharmaceuticalintelligence.com/2016/04/24/new-e-book-titles-forthcoming-on-amazon-com-in-2016-from-lpbi-groups-biomed-e-series-forthcoming-cover-pages/

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

 

GROWTH TRENDS: e-Readers, # of articles, NIH Clicks, Nature Clicks

2013, 2014, 2015, 2016

Scientific Journal Site Statistics

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

07/29/2013   217,356 1,138 1,389 705

12/01/2013   287,645 1,428 1,676 828

02/09/2014   325,039 1,665 1,793 892

03/05/2014   338,958 1,717 1,830 965

03/21/2014   347,667 1,750 1,838 974

03/31/2014  352,683 1,768 1,869 991

05/12/2014  373.696  1,878  1,944  1,035

06/18/2014  393,111  1,992  1,982  1,087

7/27/2014  418,570  2,098  2.050  1,124

9/2/2014  444,222  2,226  2,104  1,170

10/9/2014 471,117  2,337  2,147  1,216

11/4/2014  492,736  2,471  2,194 1,234

2/15/2015  572,027 2,727  2,358  1,345

3/10/2015 591,520 2,808 2,373 1,369

6/7/2015   661,215 3,007 2,562 1,535

7/27/2015 694,298 3,085 2,583 1,572

8/18/2015 709,609  3,173 2,613 1,573

02/18/2016  886,454  4,162   2,911  1,813 

Date |Views to Date |# of articles |NIH Clicks |Nature Clicks

12/1/2016 1,107,643  4,972 3,398  2,279

 

Be proud to be part of this team !!!

 

Top Authors for all days ending 2016-12-01 (Summarized)

Author Views
Aviva Lev-Ari, PhD, RN 295,929
larryhbern 203,736
tildabarliya 43,869
sjwilliamspa 35,934
Dror Nir 23,073
Dr. Sudipta Saha 19,509
ritusaxena 14,934
 
Demet Sag, Ph.D., CRA, GCP 12,025
aviralvatsa 7,942
zraviv06 7,176
zs22 3,738
anamikasarkar 3,182
danutdaagmailcom 2,283
pkandala 2,097
Gail S Thornton 2,035
Alan F. Kaul, PharmD., MS, MBA, FCCP 1,975
Aashir Awan, Phd 1,775
megbaker58 1,408
jdpmd 1,345
Irina Robu 879
Ed Kislauskis 546
howarddonohue 521
evelinacohn 344
David Orchard-Webb, PhD 341
apreconasia 332
stuartlpbi 252
jukkakarjalainen 226
gerag2015 90
kellyperlman 59
Rosalind Codrington, PhD 29
Debashree 22

 

 Top Posts for all days ending 2016-12-03 (Summarized)

 

 All Time  
 
Title
  Views
Home page / Archives 402,487
Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? – Dr. Larry Bernstein 14,861
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) Aviva Lev-Ari, et al 9,080
Recent comprehensive review on the role of ultrasound in breast cancer management Dr. Dror Nir 6,720
Paclitaxel vs Abraxane (albumin-bound paclitaxel) Tilda Barliya, PhD 5,695
Our TEAM  Aviva Lev-Ari, PhD, RN 5,539
Mesothelin: An early detection biomarker for cancer (By Jack Andraka)

Tilda Barliya, PhD

5,051
Akt inhibition for cancer treatment, where do we stand today?

Ziv Raviv, PhD

3,843
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses – Zohi Sternberg, PhD 3,740
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care – Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 3,418
Volume One: Perspectives on Nitric Oxide in Disease Mechanisms

Editors: Dr. Larry Bernstein, Aviral Vatsa, PhD and Stephen J Williams, PhD

3,389
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad – Demet Sag, PhD 3,181
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo – Stephen J Williams, PhD 3,149
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications – Aviva Lev-Ari, PhD, RN 3,082
Founder  Aviva Lev-Ari, PhD, RN 3,075
BioMed e-Series – Aviva Lev-Ari, PhD, RN 2,944
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Aviva Lev-Ari, PhD, RN et al 2,728
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology – Tilda Barliya, PhD 2,728
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets –  Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 2,715
VISION  Aviva Lev-Ari, PhD, RN 2,527
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community – Dr. Larry Bernstein, Dr. Justin Pearlman and Aviva Lev-Ari, PhD, RN 2,487
Funding, Deals & Partnerships – Aviva Lev-Ari, PhD, RN 2,436
Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I

Dr. Larry Bernstein

2,318
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules –  Stephen J Williams, PhD 2,260
Bone regeneration and nanotechnology –  – Tilda Barliya, PhD 2,252
“The Molecular pathology of Breast Cancer Progression” –  – Tilda Barliya, PhD 2,233
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging – Dror Nir, PhD 2,150
About  Aviva Lev-Ari, PhD, RN 2,036
In focus: Circulating Tumor Cells – Ritu Saxena, PhD 2,034
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation – Dr. Larry Bernstein 2,016
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical)

Larry H Bernstein, MD, FCAP and Justin D Pearlman, MD, PhD, FACC

1,983
Journal PharmaceuticalIntelligence.com – Aviva Lev-Ari, PhD, RN 1,977
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) – Justin D Pearlman, MD, PhD, FACC and Aviva Lev-Ari, PhD, RN 1,967
Problems of vegetarianism – Sudipta Saha, PhD 1,903
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment – Sudipta Saha, PhD 1,844
DNA Structure and Oligonucleotides – Larry H Bernstein, MD, FCAP 1,796
Targeting the Wnt Pathway [7.11] – Larry H Bernstein, MD, FCAP 1,759
Biosimilars: CMC Issues and Regulatory Requirements – Aviva Lev-Ari, PhD, RN 1,726
Interaction of enzymes and hormones – Sudipta Saha, PhD 1,716
Nitric Oxide and Platelet Aggregation – Dr. Venkat S. Karra, Ph.D. 1,713
CD47: Target Therapy for Cancer – Tilda Barliya, PhD 1,712
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes –

Aviva Lev-Ari, PhD, RN

1,711
Introduction to Tissue Engineering; Nanotechnology applications

Tilda Barliya, PhD

1,666
Non-small Cell Lung Cancer drugs – where does the Future lie? –

Ritu Saxena, PhD

1,658
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node – Tilda Barliya, PhD 1,583
A Primer on DNA and DNA Replication – Larry H. Bernstein, MD, FCAP 1,572
Lipid Metabolism – Larry H. Bernstein, MD, FCAP 1,568
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB

Aviva Lev-Ari, PhD, RN

1,532
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research – Stephen J Williams, PhD 1,489
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers – Aviva Lev-Ari, PhD, RN 1,459

p53 mutation – Li-Fraumeni Syndrome – Likelihood of Genetic or Hereditary conditions playing a role in Intergenerational incidence of Cancer

 

Reporter: Aviva Lev-Ari, PhD, RN

 

THIS ARTICLE IS RECOMMENDED READING TO ALL OUR e-Readers

because it is a REAL story of a high school student fighting Brain Cancer, glioblastoma multiforme (GBM)

it presents the FRONTIER OF GENOMICS, PRECISION MEDICINE, Interventional Radiology and Interventional ONCOLOGY at

Stanford University, Canary Center at Stanford for Early Cancer Detection, Stanford Medical Center and Lucile Packard Children’s Hospital

I was exposed to Li-Fraumeni Syndrome in the following article:

‘And yet, you try’ – A father’s quest to save his son

http://stanmed.stanford.edu/2016fall/milan-gambhirs-li-fraumeni-syndrome.html

 

Li-Fraumeni syndrome

Other Names for This Condition

  • LFS
  • Sarcoma family syndrome of Li and Fraumeni
  • Sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome
  • SBLA syndrome

LFS is a rare disorder that greatly increases the risk of developing several types of cancer, particularly in children and young adults.

The cancers most often associated with Li-Fraumeni syndrome include breast cancer, a form of bone cancer called osteosarcoma, and cancers of soft tissues (such as muscle) called

Soft tissue sarcoma forms in soft tissues of the body, including muscle, tendons, fat, blood vessels, lymph vessels, nerves, and tissue around joints.


(small hormone-producing glands on top of each kidney). Several other types of cancer also occur more frequently in people with Li-Fraumeni syndrome.

A very similar condition called Li-Fraumeni-like syndrome shares many of the features of classic Li-Fraumeni syndrome. Both conditions significantly increase the chances of developing multiple cancers beginning in childhood; however, the pattern of specific cancers seen in affected family members is different.

Genetic Changes

The CHEK2 and TP53 genes are associated with Li-Fraumeni syndrome.

More than half of all families with Li-Fraumeni syndrome have inherited mutations in the gene. TP53 is a tumor suppressor gene, which means that it normally helps control the growth and division of cells. Mutations in this gene can allow cells to divide in an uncontrolled way and form tumors. Other genetic and environmental factors are also likely to affect the risk of cancer in people with TP53 mutations.

A few families with cancers characteristic of Li-Fraumeni syndrome and Li-Fraumeni-like syndrome do not have TP53 mutations, but have mutations in the CHEK2 gene. Like the TP53 gene, CHEK2 is a tumor suppressor gene. Researchers are uncertain whether CHEK2 mutations actually cause these conditions or are merely associated with an increased risk of certain cancers (including breast cancer).

Inheritance Pattern

Li-Fraumeni syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to increase the risk of developing cancer. In most cases, an affected person has a parent and other family members with cancers characteristic of the condition.

Diagnosis and Management

These resources address the diagnosis or management of Li-Fraumeni syndrome:

References on LFS

SOURCE

https://ghr.nlm.nih.gov/condition/li-fraumeni-syndrome


LIVE Tweets via @pharma_BI and @AVIVA1950 for Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf The 12th Annual Personalized Medicine Conference, GENOMICS data sharing initiatives https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, … https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D.,Broad Institute

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI My Research Legacy: Broad & AHA – Launched November 13, 2016 Anthony Philippakis, M.D., Ph.D., AMAZING mind among us

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

3PMConf @pharma_BI Genetic component to become part of Patient care Recepient Leadership in Personalized Medicine Award, Raju Kucherlapati

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Kristine Bordenave, M.D., Lead Medical Director, Humana complex Clinical perspective, cost to patient, clinician, Pharma

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI 25 of 50 States are participants in MOlDx — NOT New England State Elaine Jeter, M.D., MolDx Medical Director, Palmetto

 

  1. Aviva Lev-Ari‏@AVIVA1950 Nov 17

#PMConf @pharma_BI Richard Hamermesh, Harvard Bus School led GREAT Case Study Presentation on IP disputed DNA-editing technologies, CRISPR

 

9.  Aviva Lev-Ari ‏@AVIVA1950  Nov 17

#PMConf @pharma_BI 65,000 molecular tests in the market in the Registry only 10,000 Elaine Jeter, M.D., MolDx Medical Director, PalmettoGBA

10. Aviva Lev-Ari‏@AVIVA1950 Nov 17

@pharma_BI #PMConf Daniel O’Day, CEO, Roche Pharmaceuticals is Optimistic on Personalized Med – new US Gov’t – no change in Roche Mission

11. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Pricing Drugs and THerapeutic Outcomes, The 12th Annual Personalized Medicine Conference, HMS https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf Molecular DIagnostics LIVE 11/16 1:15PM – 2:45PM – The 12th Annual PM Conference, https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

STAR @ #PMConf Eric Dishman, Director, All of Us Research Program, National Institutes of Health https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

@pharma_BI @AVIVA1950 #PMConf LIVE Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Jose… https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏@AVIVA1950  Nov 16

#PMConf @pharma_BI @AVIVA1950 covering in REAL TIME 12th Annual @PartnersPersMed at Harvard Medical School @harvardmed today + tomorrow

 

 

 


Real Time Coverage and eProceedings of Presentations on 11/16 – 11/17, 2016, The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

LIVE 11/16 8AM – noon The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-8am-noon-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 1:15PM – 2:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-115pm-245pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/16 3:15PM – 5:30PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/16/live-1116-315pm-530pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 8AM – 1:45PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-8am-145pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 

LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

https://pharmaceuticalintelligence.com/2016/11/17/live-1117-145pm-5pm-the-12th-annual-personalized-medicine-conference-harvard-medical-school-joseph-b-martin-conference-center-77-avenue-louis-pasteur-boston/

 


LIVE 11/17 1:45PM – 5PM – The 12th Annual Personalized Medicine Conference, HARVARD MEDICAL SCHOOL, Joseph B. Martin Conference Center, 77 Avenue Louis Pasteur, Boston

 

Leaders in Pharmaceutical Business intelligence (LPBI) Group

Covering in Real Time using Social Media this Event on

Personalized Medicine

Aviva Lev-Ari, PhD, RN, Founder LPBI Group & Editor-in-Chief

http://pharmaceuticalintelligence.com

Streaming LIVE @ HARVARD MEDICAL SCHOOL,

Joseph B. Martin Conference Center

@pharma_BI

@AVIVA1950

November 17

#PMConf

1:45 p.m. — Leadership in Personalized Medicine Award

  • Presenter: William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition

Science, Business and Patents: Millenium, Celgenics, and Medicine/Desease – Member of AAAS

co-Chair Cancer Consorcium

PM – 1990’s on. How Human Genome at Harvard will start a new center – reach out to the Global community, conference was born. PM as subject of a Global Conference, effirt started with Genzyme, Eric Launder, Broad, Collins at NIH – effort led to Obama Initiative in PM, Duke Medical System.

Challenge: Reimbursement for Genomics diagnosis

  • PM – P care – by sequencing of Genome – become available commercially inexpensivelly
  • Genetic component to become part and parcial of Medicine and Patient care

2:15 p.m. — Networking Break

2:45 p.m. — The Data Dilemma: Fulfilling Expectations of Big Data in the Future of Personalized Medicine

There is consensus that the massive amounts of genomic, clinical, claims and other types of data could yield important insights for research and clinical care. But for years, obstacles around technical standards, interoperability, privacy and confidentiality, data security, and consent have been held up as daunting challenges that inevitably slowed progress.  During this discussion, a panel of academic and industry experts will discuss their respective organizations’ strategies to obtain and analyze the data, including what has worked and what has not; the programs and processes that have led to the most productive data usage; examples of important knowledge that has been derived from data analysis; and the infrastructure they believe is needed to achieve fulfillment of the potential of big data in personalized medicine nationwide.

  • Moderator: Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare
  1. How one works with 20 Partners at once?

 

  • Paul Bleicher, M.D., Ph.D., CEO, OptumLabs
  1. Data collaboration of 35 Partners – bring value to Medicine, Like Bell Labs
  2. Academics, Hospitals, Physician offices – Constellations – groups of projects
  3. DATA is KEY — Public and Private Partnerships
  • Christophe G. Lambert, Ph.D., Associate Professor, Center for Global Health, Division of Translational Informatics, Department of Internal Medicine, University of New Mexico
  1. VA Data, Co-Chair of Informatics, clinical , pharmaceutical stackholders
  2. Focus Groups Patient research Partners – How to automate data
  3. Centralization above nad decentralization, below COntrol mechanism govern all variables: Increase fitness of system vs Personal Control
  4. 1984-1998 Bi-Partisan support for Data in HealthCare
  5. Big Data for early detection, prevention, `
  6. AGING, Infectious and Pediatric disease – Investment in these areas
  • Adam Margolin, Ph.D., Director, Computational Biology, Oregon Health & Science University School of Medicine
  1. Project with Intel – across institutions
  2. consorsium – success ration
  3. data sharing #1 Priority at the National Level
  4. Add value by data sharing, strategic investment in the healh system
  • Edward J. Stepanski, Ph.D., Chief Operating Officer, Vector Oncology
  1. Propriatory real time reporting to Physicians – systematic – core asset, originally,
  2. Research Group use Warehouse doing Analytics, Tools development linked with clinical data with PRO and studies based on data integretion
  3. Success is more data – PRO data informing clinical data
  4. Defragmenting the care vs drive across town for care several units disaggregated geography vs all deaprtments in one location

 

3:45 p.m. — Keynote Speaker
“Medicine and the Targeted Marketing Problem”

We live in the golden age of cloud computing and machine learning.  The organizing conundrum for the “big data era,” however, is a surprising one — the “targeted marketing problem” (i.e., the ability to better match the right customers to targeted messages). This talk will explore overlaps and similarities between the targeted marketing problem and precision medicine, and how advances in data sciences can be leveraged to create a learning medical system that in turn points to the health care system of the future.

  • Introduction: Amy Abernethy, M.D., Ph.D., Chief Scientific Officer, Senior Vice President, Oncology, Flatiron Health

 

  • Anthony Philippakis, M.D., Ph.D., Cardiologist, BWH, Chief Data Officer, Broad Institute and Partner, GV (Venture Capital)

Learning from Users

Five causes for cardiac death:

  • MI,
  • a-Fib
  • Structural
  • PE
  • Aorta dissection

PreventionGenomic Sequencingvalue in Cardiology:

  • Estonia BioBank – mutation carrier
  • Familial Hypercholesterolemia – 4 genes involved,
  • Prediction sudden cardiac death – larger data sets
  • New Model for Human Subjects Research; DIrect-to-Participant: Potentia Advantages:
  • cost, scalability, facilitate re-contact, frequent collection,
  • My Research Legacy: Broad & AHA – Launched November 13, 2016 
  • Quantified Self –>> Quantigied Physical Exam: Face dysformia, Dysarthia, Ataxia,
  • Identify every patient in the World  with this disease

 

Data sharing: Inverting the Model ; ALL OF US  – 1 Million – Precision Medicine with IBM – Mandate to innovate – Diversity: People, Geography, Health Status

Innovation in Genomic data sharing – bring data to researchers

SIX types od data wil be collected: Participant-provided Info, mHealth Data, Consent EMR

 

DATA Research CoreVanderbuilt, Verily Broad

  1. pharmacogenomics

Launch start ups cost

  1. Open source
  2. Cloud
  3. developers start ups

PLATFORM

 

GATK – workhorse of genomic data – Launched 4/2016

Partnerships: Amazon, google genomics, microsoft, IBM, Watson, 

 

Announcing: BROAD + Intel Center for Advanced Genomic Data Engineering, Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute

Reference Architecture: Design: Single node, small cluster,

 

4:30 p.m. — Closing Remarks

  • Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

 

– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_17_Program#sthash.zpTNQYKd.dpuf

 

#PMConf

SOURCE

http://www.personalizedmedicinecoalition.org/Conference/November_17_Program